U.S. Markets closed

Heat Biologics, Inc. (HTBX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.5342+0.0233 (+4.5557%)
At close: 4:00PM EDT
People also watch
NVCNEVOKEBIOIMNPSKLN
Full screen
Previous Close0.5109
Open0.5002
Bid0.3500 x 300
Ask0.7000 x 3700
Day's Range0.5002 - 0.5390
52 Week Range0.4600 - 3.3500
Volume223,342
Avg. Volume321,303
Market Cap19.03M
Beta1.28
PE Ratio (TTM)-1.05
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals20 days ago

    Durham company considers stock split to avoid delisting

    In the wake of a strategy pivot that will see Durham’s Heat Biologics (HTBX) focus on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – company stockholders have approved a plan to allow the board to call for a reverse stock split. The consideration of the reverse stock split, or reducing the number of shares outstanding to boost stock price, comes at a time when Heat is in threat of delisting from the Nasdaq exchange for failing to maintain a minimum closing bid price of $1.00. The company faced a similar situation last year, but managed to rectify it without the use of a reverse stock split .

  • American City Business Journals2 months ago

    Heat Bio pivots, will focus on combination therapies for cancer

    Along with its first quarter results, Durham’s Heat Biologics (HTBX) has outlined a new strategy focusing on combination therapies for the treatment of cancer – specifically, with checkpoint inhibitors or T cell co-stimulators – alone. The strategy comes at a time when the company has seen positive data from its ongoing Phase 2 trial of HS-110 for the treatment of lung cancer in combination with Bristol-Myers Squibb checkpoint inhibitor nivolumab,according to Heat CEO Jeff Wolf said Thursday. Heat Biologics plans to discontinue its other clinical program for the treatment of non-muscle invasive bladder cancer, along with additional preclinical programs, in order to focus those resources on combination programs, he says.

  • American City Business Journals3 months ago

    Heat Bio completes acquisition of Texas company

    Durham’s Heat Biologics (HTBX) has completed its acquisition of Austin, Texas-based immuno-oncology company Pelican Therapeutics, in a cash-and-stock deal valued at about $1.5 million . "We’ve been following Pelican and thinking about [the acquisition] for quite a while," said Heat CEO Jeff Wolf in an interview at the time of the deal’s announcement in March. "Pelican's two product candidates strengthen our portfolio in the emerging T cell activation space,” said Wolf in a statement, regarding the deal’s closing.